Aegera Therapeutics Inc.
This article was originally published in Start Up
Aegera Therapeutics Inc. was formed in May 2000 through the merger of Apoptogen Inc. and Exogen Neurosciences Inc. Aegera will build on the neural signal transduction and apoptosis platforms of its founding companies with a goal of discovering and developing therapeutics for neurodegenerative diseases, peripheral neuropathies and cancer.
You may also be interested in...
Neurodegenerative disorders represent a tremendous unmet medical need. Millions of people are affected by such diseases as Alzheimer's, Huntington's Parkinson's, MS and ALS, not to mention those suffering the neurodegenerative effects of stroke and spinal cord injury. And because many of these diseases are age-related, the already staggering numbers of patients will increase during the next several years as increasing life expectancies and changing demographics increase the percentage of older Americans. The market for neuroscience therapies is currently the fastest growing segment in pharmaceuticals, and is projected to become the leading therapeutic area within five years. Small wonder that new companies are entering the fray, hoping to capture a share of this multi-billion dollar opportunity as well as to finally offer a cure to the victims of these diseases.
In Vivo's editors pick January's most significant deals, including Roche's acquisition of Flatiron and Moderna's latest big private fundraising. (Free article.)
In Vivo's editors pick January's most significant deals, including an alliance of players new to health care and Celgene's big buys. (Free article.)